Education
About Us
Working with TipRanks
Follow Us
Immuron Ltd (IMRN)
NASDAQ:IMRN
IMRN Stock Chart & Stats
$0.82
-$0.03(-1.20%)
At close: 4:00 PM EST
$0.82
-$0.03(-1.20%)
Day’s Range― - ―
52-Week Range$0.68 - $2.39
Previous CloseN/A
Volume5.19K
Average Volume (3M)75.95K
Market Cap
$6.50M
Enterprise Value-$2.78M
Total Cash (Recent Filing)$9.99M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.14
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding8,166,340
10 Day Avg. Volume112,552
30 Day Avg. Volume75,952
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.90
Price to Sales (P/S)2.09
P/FCF Ratio-2.49
Enterprise Value/Market Cap-0.43
Enterprise Value/Revenue-0.31
Enterprise Value/Gross Profit-0.48
Enterprise Value/Ebitda0.43
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)$6.31M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Capital StructureExtremely low debt-to-equity provides durable financial flexibility: it reduces solvency risk, preserves borrowing capacity for R&D or working capital, and limits fixed finance costs. Over 2–6 months this supports runway and strategic optionality while the company scales product sales.
Stable Gross Profit Margins (~65%)Sustained ~65% gross margins indicate attractive unit economics for the colostrum-based products. High product-level margins provide scope to fund marketing, expand distribution, and absorb SG&A while pursuing commercialization, supporting margin recovery even as scale increases.
Commercial Traction And New Product ExpansionConsistent Travelan growth, a national ProIBS launch and expanded pharmacy/ecommerce distribution show real-world product-market fit and channel diversification. Durable revenue runway arises from stronger retail placement, digital marketing gains and geographic expansion rather than one-off promotions.
Bears Say
Declining Revenue And Persistent LossesRevenue contraction and entrenched negative margins indicate the core business is not yet self-sustaining. Persistent losses erode equity and limit reinvestment capacity, increasing dependency on external funding and complicating efforts to reach consistent operating profitability within the medium term.
Negative Operating And Free Cash FlowNegative operating and free cash flows signal an ongoing cash burn that constrains reinvestment and reduces financial slack. A large negative swing in free cash flow growth implies limited internal funding for commercialization, creating structural pressure to raise capital or cut investment.
Dependence On External Equity / Prior IssuancesRatification of prior placements and preservation of issuance powers reflect reliance on equity financing to fund operations. Structurally, this increases dilution risk for shareholders and signals limited internal cash generation, making future capital markets access a key business dependency.
Immuron News
IMRN FAQ
What was Immuron Ltd’s price range in the past 12 months?
Immuron Ltd lowest stock price was $0.68 and its highest was $2.39 in the past 12 months.
What is Immuron Ltd’s market cap?
Immuron Ltd’s market cap is $6.50M.
When is Immuron Ltd’s upcoming earnings report date?
Immuron Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 178 days.
How were Immuron Ltd’s earnings last quarter?
Immuron Ltd released its earnings results on Feb 25, 2026. The company reported -$0.199 earnings per share for the quarter, missing the consensus estimate of -$0.007 by -$0.192.
Is Immuron Ltd overvalued?
According to Wall Street analysts Immuron Ltd’s price is currently Overvalued.
Does Immuron Ltd pay dividends?
Immuron Ltd does not currently pay dividends.
What is Immuron Ltd’s EPS estimate?
Immuron Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immuron Ltd have?
Immuron Ltd has 8,166,340 shares outstanding.
What happened to Immuron Ltd’s price movement after its last earnings report?
Immuron Ltd reported an EPS of -$0.199 in its last earnings report, missing expectations of -$0.007. Following the earnings report the stock price went up 17.103%.
Which hedge fund is a major shareholder of Immuron Ltd?
Currently, no hedge funds are holding shares in IMRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immuron Ltd
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---